When a child is diagnosed with cancer, their family is presented with treatment options – often a combination of surgery, radiation and chemotherapy. Radiation and chemotherapy have been used to treat kids’ cancers for more than 50 years and often come with long-term late effects including secondary cancers, heart damage and cognitive issues. Often a child’s best chance at survival is a clinical trial which offers them the newest treatment options available.
In recognition of Childhood Cancer Awareness Month, the St. Baldrick’s Foundation will highlight the critical need to fund lifesaving research and share stories of kids affected by cancer – like Micah, who is alive today because there was a clinical trial available.
To view the multimedia release go to:
https://www.multivu.com/players/English/8284352-st-baldricks-foundation-conquer-childhood-cancers/
TransCelerate BioPharma Inc., a non-profit organization dedicated to improving the health of people around the world by simplifying and accelerating research and development of innovative new therapies, has unveiled a new global campaign designed to help increase awareness of the growing need for clinical trial participants. The campaign, called “One Person Closer,” focuses on inspiring healthcare professionals (HCPs) to consider clinical research as a possibility for their patients, incorporate the topic into their daily practices, and have meaningful conversations with patients about opportunities to participate in clinical trials.
One Person Closer is designed to put a human face on research and development by sharing the personal stories of researchers, HCPs and patients who have contributed to clinical research and the development of medical breakthroughs. The photojournalist campaign aims to show doctors, nurses and other HCPs that they can help facilitate research that advances science and that may benefit their patients.
To view the multimedia release go to:
https://www.multivu.com/players/English/8268751-transcelerate-biopharma-one-person-closer/
Chaleur-Beauty Enhanced by Heat, the world’s first self-heating skin care system, is launching direct-to-consumers with a with a no pressure trial offer that’s one hundred percent guaranteed to produce results. The beauty brand is the first and only product that combines heat with active ingredients, allowing one thousand times the penetration versus traditional topical skin care– pushing active ingredients in while pulling out toxins.
“One self-heating mask along with Chaleur’s Ageless Facial Gel creates the ideal environment to allow special ingredients, including our patented enzyme, to penetrate layers of the skin,” said Chad Law, CMO of Chaleur Beauty.
To view the multimedia release go to:
https://www.multivu.com/players/English/8210451-chaleur-beauty-self-heating-skin-care-launch/
Decorated U.S. war veteran Romulo (Romy) Camargo starts his day like most of us. He wakes up, gets a drink of water, has some breakfast, brushes his teeth, and gets dressed. But for Camargo, whose injuries in Afghanistan left him paralyzed from the neck down, these morning routines require some assistance. And Toyota is learning how to help.
Thanks to Camargo, Toyota recently completed the first North American in-home trial of the Human Support Robot (HSR). The HSR is one of the “partner robots” Toyota is developing to assist people with everyday activities. Toyota is actively researching ways to apply advanced technologies to help people with limited mobility, including seniors or those who are disabled.
To view the multimedia release go to:
https://www.multivu.com/players/English/8053352-toyota-human-support-robot-mobility-disability/
Today, WebMD released In Their Own Words: Moving Beyond Migraine with Robin Roberts, a new five-part video series that sheds light on the debilitating nature of migraine and the impact it has on all aspects of a sufferer’s personal and professional life.
To learn more about treatments and the individuals featured in In Their Own Words: Moving Beyond Migraine with Robin Roberts, visit: to www.webmd.com/insidemigraines.
Moving Beyond Migraine follows the lives of Jennifer, a public school administrator who has lived with intense migraine headaches for over 20 years; Kate, a 20-year-old college student with debilitating migraines that have run in her family for generations; Melanie, whose intense migraine condition has altered the dynamics of her nine year marriage; and Lynn, who after suffering from migraine for 50 years, shares how a clinical trial for a new treatment called CGRP targeted therapy is finally providing her with some relief.
To view the multimedia release go to:
https://www.multivu.com/players/English/7579759-robin-roberts-moving-beyond-migraine/
A ten-month clinical trial at Sentara Leigh Hospital in Norfolk, Virginia has determined that hard surfaces and linens infused with copper oxide compounds contributed to an 83% reduction in C-difficile and a 78% overall reduction in a host of multi-drug resistant organisms (MDROs) including C-diff, MRSA and VRE in a real-world clinical environment. These results occurred in a hospital with a robust protocol for managing infection risk certified by the health care accrediting body DNV-GL Healthcare.
The results of the trial were published in the peer-reviewed American Journal of Infection Control on Sept. 28, 2016 and will be presented at the annual conference of the Infectious Disease Society of America in New Orleans, Louisiana on October 27, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7955751-sentara-healthcare-infections-copper-clinical-trial/
A ten-month clinical trial at Sentara Leigh Hospital in Norfolk, Virginia has determined that hard surfaces and linens infused with copper oxide compounds contributed to an 83% reduction in C-difficile and a 78% overall reduction in a host of multi-drug resistant organisms (MDROs) including C-diff, MRSA and VRE in a real-world clinical environment. These results occurred in a hospital with a robust protocol for managing infection risk certified by the health care accrediting body DNV-GL Healthcare.
The results of the trial were published in the peer-reviewed American Journal of Infection Control on Sept. 28, 2016 and will be presented at the annual conference of the Infectious Disease Society of America in New Orleans, Louisiana on October 27, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7955751-sentara-healthcare-infections-copper-clinical-trial/
Going on the offensive against one of the most daunting challenges in cancer, The Leukemia & Lymphoma Society (LLS) today announced the launch of a groundbreaking, collaborative clinical trial for acute myeloid leukemia (AML), a deadly disease which has seen few improvements in treatments in more than 40 years.
Beat AML was announced yesterday by Vice President Biden, along with many new, Moonshot inspired initiatives across industry, non-profit and government.
AML is the most lethal of the blood cancers, which together are the third leading cause of cancer deaths in the U.S.; AML is responsible for more than 10,000 deaths each year. Despite advances in treating other blood cancers, the standard of treatment for AML – a combination of toxic chemotherapies – has remained the same for more than 40 years. Overall prognosis remains poor, with a five-year survival rate below 20 percent for patients over age 60.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554854-lls-beat-aml-acute-myeloid-leukemia/
World trade in perishable foods turns a page as Maersk Container Industry (MCI), an independent business unit in the Maersk Group conglomerate, today announced that it has begun production of the first refrigerated containers and Star Cool refrigeration machines built in South America at its new MCI facility in San Antonio, Chile.
The first trial production of these ISO standard 40 feet reefer containers were successfully delivered during the third quarter of 2015 into the Maersk Line and CMA CGM operations. Shortly thereafter, both shipping lines placed new orders. To further leverage this new value proposition, Maersk Line has secured a fixed monthly volume from the MCI facility allowing for increased agility and fast response time to the demand in the region.
“In this sweet spot of fruit exporters, we have placed the factory right where the demand is. For the first time ever in South America, reefer containers can go straight “from factory to farm”,” said Stig Hoffmeyer, Chief Executive Officer of MCI. “Offering the Star Cool Integrated reefers locally to shipping lines, farmers, fruit distributors and leasing companies, will have a financial benefit counted in thousands of dollars per reefer, and millions for the industry in total,” he continued.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7688551-maersk-container-industry-factory-chile/
Off the coast of Central America, the Sea Diva, a tuna boat, sinks. Members of the crew are missing and what happened remains a mystery. As the case goes to trial, a missing crew member is believed to be at fault, but new evidence comes to light and the finger of guilt points in a completely unanticipated direction. Learn more here: http://bit.ly/1LHfMJ0
Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
Data presented today at the World Diabetes Congress of the International Diabetes Federation (IDF) show that adults with type 2 diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia for the full trial period, and a significantly lower rate of severe hypoglycaemia during the maintenance period (defined as week 16 onwards) with Ryzodeg® compared to biphasic insulin aspart 30, both administered twice-daily1.
Ryzodeg® is the first combination of two distinct insulin analogues, Tresiba® (insulin degludec), the once-daily basal insulin with an ultra-long duration of action, and the well-established mealtime insulin NovoRapid® (insulin aspart), in the ratio of 70% and 30%, in one pen for people with type 2 diabetes2-4.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64158-ryzodeg-improved-glycaemic-control
